This year, Komen announced $30.7 million in research funding for 98 research grants which will mostly focus on discovering new treatments and improving our understanding of the most lethal forms of breast cancer – helping us move closer to achieving our Bold Goal.
For the first time, Komen will be giving members of the public an opportunity to directly fund specific research by participating in a crowdfunding initiative on Komen’s website.
We wanted to share with you the grant process and how the 2017 portfolio breaks down this year since 75% of net proceeds from your fundraising support this research and we could not accomplish any of this work without you.
Komen has a renowned peer-review process – lead by Komen’s Scientific Advisory Board (SAB) – that ensures the organization is funding the best and most imperative forms of research. Advocates and breast cancer patients also take part in peer-review, to ensure all aspects of breast cancer needs are being covered. You can learn more about peer-review here.
The 2017 research grants came through the request for applications (RFA) issued last year, prior to the Bold Goal announcement in September of 2016. Still, 41.3% of Komen’s grants are focusing on metastatic breast cancer research and 54.4% of grants are focusing on new treatments.
The 2018 process for new proposals began in April and all applications submitted were asked to directly support Komen’s efforts towards the Bold Goal. Researchers were invited to submit projects that addressed metastasis or resistance to current therapies.
In 2017, Komen research funding went to institutions in 27 states and across 8 countries. The majority of grants are focusing on new screening technologies, metastatic and aggressive types of breast cancer and understanding and addressing disparities in breast cancer. By targeting metastatic disease – which is responsible for almost all of the nation’s 40,000 annual breast cancer deaths – Komen is hoping to reduce breast cancer deaths in the U.S. dramatically. To date, Komen has funded more than $180 million in metastatic breast cancer research. 2017 funding also includes $17.6 million to early-career investigators which helps to ensure a continuum of breast cancer research across generations.
Komen’s 2017 portfolio includes*:
- 37 grants expanding our knowledge of metastatic breast cancer and how to better treat it or prevent it;
- 42 grants looking into triple negative breast cancer, an aggressive subtype of breast cancer; 59 grants focused on new therapies;
- 24 investigating drug resistance (why drugs stop working in some patients);
- 9 on disparities in breast cancer outcomes;
- As well as projects investigating inflammatory breast cancer, early detection, prevention, Big Data and more.
This fall, Komen is making it possible for supporters to make a personal impact on breast cancer research. During National Breast Cancer Awareness Month in October, Komen will highlight four metastatic breast cancer researchers and encourage donations to their specific grants. More information on the crowdfunding initiative will be announced in October.
When you walk and raise money you are making a direct contribution to our grants. Funds that you raise through 3-Day could support a young scientist for a day working toward finding the cures, or could support an oncologist for a day as they run clinical trials to find the cures for breast cancer. We could not fund potentially lifesaving research without your help and support. Thank you for the impact that you make here at Komen and always being More Than Pink.
You can learn more about Komen’s 2017 funding here.
You must be logged in to post a comment.